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Abstract
The research community at large is expending considerable resources to sequence the coding region of the genomes
of tumors and other human diseases using targeted exome capture (i.e., “whole exome sequencing”). The primary
goal of targeted exome sequencing is to identify nonsynonymous mutations that potentially have functional conse-
quences. Here, we demonstrate that whole-exome sequencing data can also be analyzed for comprehensively moni-
toring somatic copy number alterations (CNAs) by benchmarking the technique against conventional array CGH.
A series of 17 matched tumor and normal tissues from patients with metastatic castrate-resistant prostate cancer
was used for this assessment. We show that targeted exome sequencing reliably identifies CNAs that are common
in advanced prostate cancer, such as androgen receptor (AR) gain and PTEN loss. Taken together, these data suggest
that targeted exome sequencing data can be effectively leveraged for the detection of somatic CNAs in cancer.
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Introduction
Recognition that copy number alterations (CNAs) in tumor genomes,
which can result in the amplification of oncogenes or the deletion of
tumor suppressors, contribute significantly to cancer etiology has led
to the development of multiple techniques for their comprehensive
identification. Initial global approaches for CNA detection relied pri-
marily on array based technologies: whole-genome array comparative
genomic hybridization (aCGH) tests the relative frequency of probe
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DNA segments between two genomes [1–4], whereas single-nucleotide
polymorphism (SNP) arrays measure the probe intensities at known
SNP loci to identify shifts in zygosity relative to another genome
[5–9]. The recent advent of high-throughput sequencing has made
the sequencing of whole human genomes feasible and has made pos-
sible the development of sequencing-based approaches to CNA iden-
tification [10–17].
The prohibitive cost and time constraints of whole-genome sequenc-
ing has necessitated further innovation, and hybridization-based
approaches to high-throughput sequencing that focus on the human
exome have been recently applied to detect novel somatic pointmutations
in tumor genomes [18–22]. Targeted exome sequencing allows one to
achieve very high depths of coverage (100× coverage or greater) of re-
gions of interest and thus provides advantages over whole-genome
sequencing for mutation detection especially in the context of the highly
deranged genomes of many tumors. Because targeted exome sequencing
yields depth of coverage data, it is reasonable to ask whether exome
sequencing data can also be used to detect CNAs, especially because a
recent application to unmatched cancer cell lines indicated the potential
of this approach [23]. In addition, the recent development of third-
generation sequencing approaches has made sequencing of a tumor
exome achievable within a week, making its application to detect so-
matic mutations in a clinical setting imminent. As a result of its wide
applicability, there would be a clear and demonstrable advantage to
applying exome sequencing to generate CNA data because it would
obviate the need for performing aCGH or whole-genome sequencing
to detect CNAs in patients awaiting treatment.
Here we propose a method for the detection of somatic CNAs from
exome sequencing of a matched tumor/normal pair. By comparing
depth of coverage across the exome between the tumor and normal
samples, we detect regions with predicted copy gain or loss in the tumor
sample. A comparison of these data to aCGH copy number data for
the same samples demonstrates a high level of agreement between
the two platforms. We apply our method to identify copy number
aberrations from exome data generated for 17 prostate tumor-normal
pairs, showing that our method identifies aberrations in multiple genes
known to have copy number gains and losses in prostate cancer in-
cluding AR, NCOA2, PTEN, RB1, and TP53 [24]. Together, these
analyses show that exome sequencing data, in addition to being useful
for detecting point mutations and indels, can be used in place of aCGH
and whole-genome sequencing for the generation of CNA data.
Materials and Methods
Tissue Samples
Prostate tissues were from the radical prostatectomy series at the Uni-
versity of Michigan and from the Rapid Autopsy Program [25], both
of which are part of the University of Michigan Prostate Cancer Spe-
cialized Program of Research Excellence Tissue Core. All samples were
collected with informed consent of the patients and previous institu-
tional review board approval.
High–Molecular Weight Genomic DNA Isolation
Frozen tissue samples were taken as chunks or sections from OCT-
embedded, flash-frozen tissue blocks. Genomic DNA (gDNA) was
isolated using the Qiagen DNeasy Blood and Tissue Kit (Valencia,
CA) according to the manufacturer’s instructions. Briefly, cell or tissue
lysates were incubated at 65°C in the presence of proteinase K and SDS,
purified on silica membrane-based mini columns, and eluted in buffer
AE (10 mM Tris-HCl and 0.5 mM EDTA pH 9.0).
Exome Capture Sequencing
Exome libraries of matched pairs of tumor/normal gDNAs were gen-
erated using the Agilent SureSelect Human All Exon Kit (Agilent, Santa
Clara, CA; the 38-Mb kit, including 165,637 exon targets, was used on
three tumor/normal matched pairs and the 50-Mb kit, including
213,050 exon targets, was used on the remaining 14; Table W2) and
the Illumina Paired-End Genomic DNA Sample Prep Kit (Illumina,
San Diego, CA) following the manufacturers’ instructions. Three micro-
grams of each gDNAwas sheared using a Covaris (Woburn,MA) S2 to a
target peak size of 250 bp. Fragmented DNA was concentrated using
AMPure XP beads (BeckmanCoulter, Indianapolis, IN), andDNA ends
were repaired using T4 DNA polymerase, Klenow polymerase, and T4
polynucleotide kinase. 3′ A-tailing with exo-minus Klenow polymerase
was followed by ligation of Illumina paired-end adapters to the gDNA
fragments. The adapter-ligated libraries were electrophoresed on 3%
Nusieve 3:1 (Lonza, Walkersville, MD) agarose gels, and fragments
between 250 and 350 bp were recovered using QIAEX II gel extraction
reagents (Qiagen). Recovered DNA was then amplified using Illumina
PE1.0 and PE2.0 primers for nine cycles. The amplified libraries were
purified using AMPure XP beads, and the DNA concentration was
determined using a Nanodrop spectrophotometer (NanoDrop 8000;
Thermo Scientific, Wilmington, DE). Five hundred nanograms of the
libraries was hybridized to the Agilent biotinylated SureSelect Capture
Library at 65°C for 65 hours. The targeted exon fragments were captured
on Dynal M-280 streptavidin beads (Invitrogen, Carlsbad, CA), washed,
eluted, and enriched by amplification with the Illumina PE1.0/PE2.0
primers for eight additional cycles. After purification of the polymerase
chain reaction products with AMPure XP beads, the quality and quan-
tity of the resulting exome libraries were analyzed using an Agilent Bio-
analyzer (Agilent). All captured DNA libraries were sequenced with the
Illumina HiSeq 2000 (Illumina) in paired-end mode trimmed to yield
78-bp reads. The reads that passed the chastity filter of Illumina BaseCall
software were used for subsequent analysis. Next, mate pairs were pooled
and then mapped as single reads to the reference human genome (NCBI
build 36.1, hg18), excluding unordered sequence and alternate haplo-
types, using Bowtie [26], keeping unique best hits, and allowing up to
two mismatched bases per read.
Array Comparative Genomic Hybridization
aCGH of six samples (matched tumor and normal) from three
metastatic prostate cancer patients was performed using gDNA on
Agilent’s 244K aCGH microarrays (Human Genome CGH 244K
Oligo Microarray) using Agilent’s Standard Direct Method protocol
and Wash Procedure B. Briefly, 1.5 to 3 μg of gDNA from prostate
specimens (isolated as above) was restriction digested with AluI and
RsaI, labeled with Cy-5 (test channel), purified using Microcon YM-
30 columns (Millipore, Hayward, CA), and hybridized with an equal
amount of Cy-3 (reference channel)-labeled human male gDNA
(Promega, Madison, WI) for 40 hours at 65°C. Posthybridization wash
was performed with acetonitrile wash and Agilent Stabilization and
Drying Solution wash. Scanning was performed on an Agilent scanner
(Model G2505B; 5-μm scan with software v7.0), and data were
extracted using Agilent Feature Extraction software v9.5 using protocol
CGH-v4_95_Feb07.
For data analysis, quantifications for each probe were determined as
rProcessedSignal/gProcessedSignal and analyzed on the log2 scale. To
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focus on somatic copy number changes, log2 ratios in the matched nor-
mal sample were subtracted from the log2 ratios in each tumor sample,
and the resulting differences were used for analysis. Replicate probes
on the array were summarized by computing the median value across
replicates for each sample and using this median for analysis. The
resulting log2 ratios were median centered for each tumor/normal
matched pair.
Segmentation Analysis
Segmentation analysis for both aCGH and exome log2 copy number
ratios was performed through the use of the Circular Binary Segmen-
tation Algorithm [27], as implemented in the DNAcopy package in R
version 2.11.1. Default values for all parameters were used, except that
consecutive segments were merged using the undo.splits = “sdundo”
option with the undo.SD parameter set to 0.3/DLRS, where DLRS
(derivative log ratio spread) represents the local SD in log ratio units, a
well-known measure of local variability for aCGH microarrays. In this
way, the segmentation algorithm was tuned to detect copy number
changes of at least 0.3 in magnitude on the log2 scale. Segments were
reported as amplified or deleted if the corresponding estimated copy
number ratio was greater than 1.25 or less than 0.75, respectively;
high-level amplifications and homozygous losses were called whenever
the estimated copy number ratio was greater than 2.0 or less than 0.5.
ROC analysis was performed using the ROC package in Bioconductor.
Informative Genes
The list of 2016 “informative” cancer genes used to quantify perfor-
mance of copy number calls was generated by combining the list of
457 genes comprising the Sanger Institute’s Cancer Gene Census to-
gether with a list of 1933 Protein Kinases, Tumor Suppressors, Tyrosine
Kinases, and Oncogenes downloaded from Memorial Sloan-Kettering
Cancer Center’s Cancer Genes resource. This resulted in a list of 2217
unique genes, of which 2016 were targeted by the Agilent SureSelect
Human All Exon Kit and did not map to the Y chromosome.
Results
Algorithm: Detecting Copy Number Alterations from Whole
Exome Sequencing Data
Figure 1 illustrates our approach to generating copy number data
from whole exome sequencing data. Libraries are prepared from tumor
and matched normal DNA, targeted exons are sequenced, and per-exon
coverage is computed for both tumor and normal samples. In contrast
to genomic sequencing, in which depth of coverage is approximately
proportional to genomic copy number [11], exome sequencing in-
volves varying capture efficiencies across the human exome, making
the relationship between coverage and copy number less apparent.
We accounted for variation in coverage across exons by performing
per-exon comparisons between each tumor sample and its matched
normal sample. This approach also corrects for variation in observed
coverage across different regions of the human genome due to the
presence of repetitive sequences and variation in GC content.
More precisely, we generated copy number ratios for each tumor/
normal matched pair through the following algorithm. First, exons con-
taining fewer than 10 reads (i.e., 780 bp) worth of coverage in the
matched normal sample were excluded from analysis. Second, coverage
values were perturbed slightly by adding 780 bp of coverage to each
exon’s coverage quantification in both samples. Third, per-exon cov-
erage in the tumor sample was divided by per-exon coverage in the
matched normal sample, resulting in coverage ratios for each exon.
These modified coverage ratios were then globally normalized by di-
viding each of them by the ratio of human mappings between the two
samples (tumor/normal). After log2-transforming these normalized
coverage ratios, the overall median value was subtracted, resulting in
a set of log2-transformed coverage ratios with median zero for each
tumor/normal matched pair. Ratios and logarithms were well defined
throughout this process owing to the filtering of low-coverage exons in
the benign sample, which ensured that division by zero did not occur,
and the small perturbation of coverage values, which ensured that cov-
erage ratios were always nonzero. The normalized log2-transformed
coverage ratios were used for downstream segmentation analysis. The
resulting data structure is analogous to that of a two-channel microarray
with “probes” at each targeted exon and sequencing coverage replacing
signal intensity.
Benchmarking: Concordance with Copy Number Alterations
Generated Using aCGH
We investigated the ability of these normalized exome capture cover-
age ratios to yield accurate copy number assessments by comparing them
against the corresponding copy number ratios from Agilent 244K CGH
microarray data. We used three matched metastatic castration-resistant
prostate tumor/normal pairs for this comparison, using the 38-Mb
Figure 1. Overview of copy number analysis by whole exome sequencing. Vertical bars represent per-exon coverage in the tumor (red)
and matched normal (black) tissue. Log-transformed coverage ratios between tumor and normal tissues are computed for each exon
(black dots) and altered regions are identified through segmentation analysis (red line segments).
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Agilent SureSelect Human All Exon Kit to target the human exome and
performing next-generation sequencing on the Illumina HiSeq 2000
platform. Representative assessments for one sample WA54 are shown
in Figure 2 with assessments for the other two samples in Figures W1
and W2. Genome-wide copy number ratios are highly concordant be-
tween the two technologies (Figure 2A) with large-scale amplifications
agreeing in magnitude. Large regions of gain and loss spanning whole
chromosomes and chromosomal arms, such as chromosome 7 gain,
8p loss, 8q gain, 16p gain, 16q loss, 18q loss, and Xp gain, are easily
visible by both technologies. We verified this concordance more formally
by comparing copy number ratios on disjoint windows covering the ge-
nome. Specifically, we partitioned the genome into windows containing
at least five targeted exons and five aCGH probes and computed mean
log ratios by each technology on each window. The resulting quanti-
fications exhibit strong correlations for each of the three samples (mini-
mum Pearson correlation coefficient = 0.92, P < .001; Figure W3). This
genome-wide comparison illustrates that copy number ratios from
exome capture sequencing exhibit strong concordance with and are on
the same scale as those from aCGH microarrays.
In addition, we examined copy number at genes well known to be
gained or lost in prostate cancer and found that copy number assess-
ments for these genes were concordant as well. Both technologies
Figure 2. Comparison of exome sequencing to array CGH in detecting CNAs. (A) Overall copy number across the genome for metastatic
prostate tumor sample WA54 by aCGH (upper panel) and exome sequencing (lower panel). Log2(copy number ratio) between tumor and
matched normal is shown on the vertical axis; each point represents the log-transformed ratio for each aCGH probe or targeted exon,
ordered by genomic coordinates. (B) Copy number assessment for sample WA54 by aCGH and exome sequencing in a 35-Mb region
containing the AR gene. Red line segments represent segmented copy number data. (C) Copy number assessment for sample WA54 by
aCGH and exome sequencing in a 30-Mb region containing the PTEN gene. Red line segments represent segmented copy number data.
(D) Classification performance of exome capture sequencing relative to aCGH for sample WA54. ROC curves are shown, using aCGH copy
number assessments as a criterion standard. ROC curves are presented for classifying all aCGH segments (red), segments containing at
least 10 targeted exons (green), and all targeted genes (blue).
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Figure 3. Qualitative comparison to prior CNAs observed in prostate cancer. (A) Overall summary of copy number across 17 lethal
metastatic castration-resistant prostate cancers. Summed segmented log2 copy number ratios (top panel) for all targeted genes across
the 17 samples are shown. Genes exhibiting recurrent amplifications or deletions across the cohort will have large positive or negative
values, respectively. Regions of copy number gain and loss for all 17 samples are shown in a heat map (bottom panel). Red represents
amplification; white, copy number neutral; blue, deletion. Three samples are derived from three different metastatic foci from a man
with lethal castrate-resistant prostate cancer: celiac lymph node metastatic site (WA43-27), lung metastatic site (WA43-71), and bladder
metastatic site (WA43-44). (B) Focal amplifications of the AR gene and deletions of the PTEN gene in this cohort. AR has the largest
positive summed log copy number ratio across the 17 samples, with a total sum of 32.6, whereas PTEN has the largest negative
summed log copy number ratio, with a total sum of −17.5. A plot of this sum over the entire chromosome (top) is shown; a large
positive peak is present at AR and a large negative peak is present at PTEN. Segmented copy number ratios are represented by boxes,
with the area (absolute log2 ratio) and color intensity (log2 ratio; copy number gain in red; loss in blue) of each box proportional to mean
copy number across that gene. Missing boxes indicate that the gene is neither amplified nor deleted in that sample.
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reveal a focal amplification of the AR gene in sample WA54 (Figure 2B),
and the patterns of copy number changes in that region are strikingly
similar. The estimated number of copies in the segment overlapping
the AR gene was similar by each approach (4.50 copies by aCGH,
4.57 copies by exome capture), revealing that exome capture coverage
ratios exhibit sufficient dynamic range to capture high-level ampli-
fications. Similarly, both aCGH and exome sequencing reveal a focal
region of two-copy loss at the PTEN gene in sample WA54 (Fig-
ure 2C), and the two technologies agree on the approximate number
of copies: 0.27 copies of PTEN by aCGH and 0.22 copies of PTEN
by exome capture.
To quantify the ability of exome capture sequencing to identify re-
gions of gain and loss, we performed ROC analysis of exome capture
quantifications, using the matched aCGH data as a criterion standard
(Figure 2D). First, we performed segmentation analysis (Materials and
Methods) on both aCGH and exome capture log-transformed copy
number ratios, and using copy number ratio cutoffs of 1.25 and 0.75
to define regions of gain and loss, respectively, we identified a set of
altered regions by aCGH. The segmented exome capture copy number
ratios were computed on these altered segments; performance of this
classifier relative to the aCGH calls was quantified using the area under
the ROC curve (AUC). For each of the three samples, exome copy
number analysis performed well in classifying these aCGH segments,
with AUCs of at least 0.89 across the three samples (Table W1). As
expected, restricting attention to segments that contain targeted exons
improved classification performance; for segments containing at least
two targeted exons, the minimum AUC across the three samples was
0.94. Finally, we did a gene-centric analysis, comparing copy number
calls for each of the 18,090 genes targeted by the exome capture kit,
and performance was even better, with a minimum AUC of 0.989
across the three samples. We repeated this analysis for a smaller set of
2016 “informative” genes (Materials and Methods) that have been
implicated in cancer (e.g., kinases, oncogenes, and tumor suppressors)
and verified that the strong performance persists when restricted to
genes that are likely to be relevant to cancer progression.
Application: Copy Number Alterations in Prostate
Cancer Tissues
Next, we sought to demonstrate that our CNA detection method
can be used to generate results qualitatively equivalent to aCGH-based
methods by applying it to the exomes of 17 lethal metastatic castration-
resistant prostate cancers (Table W2), including the three samples used
for benchmarking, and matched normal tissues from the same patients.
In total we generated 395,489,506,152 bases, with 105.27 average fold
coverage of each targeted base per tissue sample (Table W3). Using
copy number ratio cutoffs of 1.25 to define regions of gain and 0.75
to define regions of loss, we identified a median of 93 gained regions
and 79 lost regions across the 17 samples (TableW4). Themedian total
length of these altered regions across samples was 407.5 Mb (gains)
and 406.2 Mb (losses). Using more stringent copy number ratio cut-
offs of 2.0 to define high-level gain and 0.5 to define homozygous loss
identified a median of 19 high-level gains and 17 homozygous losses
covering 23.3 and 25 Mb, respectively. Three of the cancer samples
were derived from different metastatic sites from the same patient;
these three samples had multiple amplifications and deletions in com-
mon, including focal amplifications on chromosomes 4 and 14, the
broad 8q amplification, loss of chromosome 22, and a focal loss on
the end of 2q, reflecting the likely clonal origin of the tumor (Figure 3A).
Global analysis of copy number profiles of all 17 prostate cancers
(Figure 3A) identified recurrent aberrations previously associated with
prostate cancer development and progression, including broad losses of
1p, 8p, 6q, and losses of large regions of chromosome 13, 15, 18 and
22, as well as gains of 1q, 3q, 7q, and 8q, containing two prostate
cancer oncogenes, MYC and NCOA2 [24,28–30]. We also identified
previously reported deletions between TMPRSS2 and ERG in cases with
TMPRSS2:ERG gene fusions [24,28–30]. In addition, we identified
recurrent focal amplifications of AR (Figure 3B) and recurrent homo-
zygous focal deletions of PTEN (Figure 3C), consistent with prior obser-
vations [24,28–30]. Examination of each sample’s copy number ratio
in these regions shows that the pattern of nearby amplifications around
AR can be different for each sample; however, the region of gain always
includes AR itself. The same is true with respect to the region of loss
including PTEN. We also detected specific disruptions of RB1 and
TP53 (Figure 3A), two genes previously associated with focal losses in
prostate cancer [24,28,30].
Discussion
There are a number of benefits of using targeted exome sequencing for
assessing CNAs. One benefit of the exome-based approach to identify-
ing CNAs, over using evenly spaced genomic hybridization probes in
aCGH, is the possibility of using the data to gain exon-level resolution
of the genomic rearrangements associated with copy number changes.
Another benefit is that one has the potential to leverage a vast amount
of data that is already being generated as part of large genome sequenc-
ing projects, such as The Cancer Genome Atlas (TCGA). For example,
at the time of writing, the TCGA project had just released 316 whole
exomes from ovarian cancer [22], more than 500 whole exomes had
just been published, and sequencing for thousands more was underway.
In essence, point mutations (such as BRAF V600E) and amplifications/
deletions (such as amplification of ERBB2 or loss of PTEN) can be
monitored from the same whole exome sequencing data set. This type
of assessment will be powerful for integrative mutational studies in the
context of cancer and toward personalized medicine.
Sequencing-based approaches to copy number detection have the
advantage of being able to not only assess CNAs using depth of cov-
erage, like aCGH, but also using SNPs or somatic point mutation to
assess for shifts in zygosity indicative of copy number changes, as in
SNP array approaches. In this study, we have presented a depth of
coverage approach to detect CNAs using exome data, but an approach
using SNPs or somatic point mutation is equally feasible in theory.
Moreover, a combined approach using both depth of coverage and
SNPs has the potential to be even more effective, especially compared
with both aCGH and SNP arrays.
As intimated, the exome approach is limited by mapping issues,
making genes containing highly repetitive sequence difficult to target
for exome sequencing and therefore difficult to assess for CNAs using
this method. For example, the second exon of FOXA1, a two-exon
gene, has two large gaps in coverage in both the 38- and the 50-Mb
Agilent SureSelect All Human Exon design, resulting from repetitive
sequence, so that the computed coverage of the exon is always a gross
underestimate of the actual coverage. These sorts of coverage issues
make detection of focal CNAs of certain genes difficult. A second
limitation is that exome capture copy number analysis will clearly fail
to detect genomic aberrations that occur in regions containing no near-
by genes. If exome capture was deliberately used for assessing CNAs,
both limitations could be overcome by optimizing the exome capture
design to improve detection of these alterations using the excess
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sequencing capacity afforded by deep sequencing of only the coding
regions of the genome (which represent <1% of the genome). The re-
sults of this analysis suggest that additional effort should also be put
toward designing exon capture platforms that add additional targets to
improve detection of CNAs. This could be done by placing additional
targets throughout the genome and near genes with highly repetitive
regions, even if they are not directly sequencing a region of interest.
Personalized medicine approaches that emphasize somatic mutations
in informative coding genes would clearly benefit from an exon capture
platform and could efficiently assess genes of interest for both somatic
point mutations and for somatic CNAs.
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Figure W1. Concordance of aCGH and exome capture copy number assessments in sample WA53. (A) Overall copy number across the
genome for sample WA53 by aCGH and exome sequencing. Log2(copy number ratio) between tumor and matched normal is shown on
the vertical axis; each point represents the log-transformed ratio for each aCGH probe or targeted exon, ordered by genomic coordinates.
Large-scale amplifications and deletions are visible and agree in magnitude across the two technologies. (B) Copy number for sample
WA53 by aCGH and exome sequencing in a 35-Mb region containing the AR gene. Both technologies reveal the same focal pattern of
amplification and give similar estimates of the number of copies of the AR gene. Red line segments represent segmented copy number
data. (C) Copy number for sample WA53 by aCGH and exome sequencing in a 30-Mb region containing the PTEN gene. Both technologies
reveal focal 2-copy loss of PTEN in this sample. Red line segments represent segmented copy number data. (D) Classification performance
of exome capture sequencing relative to aCGH for sample WA53. ROC curves are shown, using aCGH copy number assessments as a
criterion standard. ROC curves are presented for classifying all aCGH segments (red), segments containing at least ten targeted exons
(green), and all targeted genes (blue).
Figure W2. Concordance of aCGH and exome capture copy number assessments in sample WA55. (A) Overall copy number across the
genome for sample WA55. Log2(copy number ratio) between tumor and matched normal is shown on the vertical axis; each point repre-
sents the log-transformed ratio for each targeted exon or aCGH probe, ordered by genomic coordinates. Large-scale amplifications and
deletions are visible and agree in magnitude across the two technologies. (B) Copy number for sample WA55 by aCGH and exome se-
quencing in a 35-Mb region containing the AR gene. Both technologies reveal the same focal pattern of amplification and give similar
estimates of the number of copies of the AR gene. Red line segments represent segmented copy number data. (C) Copy number for sample
WA55 by aCGH and exome sequencing in a 15-Mb region containing the TP53 gene. Both technologies reveal focal one-copy loss of TP53
in this sample. Red line segments represent segmented copy number data. (D) Classification performance of exome capture sequencing
relative to aCGH for sample WA55. ROC curves are shown, using aCGH copy number assessments as a criterion standard. ROC curves are
presented for classifying all aCGH segments (red), segments containing at least ten targeted exons (green), and all targeted genes (blue).
Figure W3. Concordance of copy number by aCGH and targeted exome sequencing through genomic windows analysis. Scatterplots
show log2 copy number ratios by each of aCGH and exome sequencing, computed as mean log2 ratios over windows covering the
genome. Windows were chosen to include at least five aCGH probes and at least five targeted exons to enable reliable comparison.
For each sample, the mean log2 copy number ratios were very highly correlated (WA53; 0.92, WA54; 0.96, WA55; 0.97, P < .001 for
each sample).
Table W1. AUC Results for Exome Sequencing Compared with aCGH.
Gain Loss
WA53 WA54 WA55 WA53 WA54 WA55
All segments* 0.971 0.913 0.946 0.956 0.902 0.896
Segments containing ≥2 exons† 0.979 0.945 0.970 0.957 0.956 0.942
Segments containing ≥10 exons† 0.979 0.977 0.982 0.951 0.958 0.946
All genes‡ 0.993 0.989 0.997 0.994 0.993 0.995
Informative genes§ 0.984 0.991 0.998 0.997 0.991 0.994
*ROC curves for predicting aberration status (gain vs no gain or loss vs no loss) of each segment
identified from segmentation analysis of aCGH data.
†ROC curves for predicting aberration of each segment identified from segmentation analysis of
aCGH data, excluding segments overlapping fewer than 2 (or 10) targeted exons.
‡ROC curves for predicting aberration status of each gene targeted by exome sequencing.
§ROC curves for predicting aberration status of each informative gene targeted by exome sequencing.
Table W2. Prostate Cancer Tissue Specimens Used for Exome Sequencing.
Sample Name Disease State* Age† Gleason Score‡ Prior Treatment§ ETS/RAF Status¶
WA53 CRPC 68 NA H, C, X ERG+
WA54 CRPC 73 NA P, R, H, C, X ERG+
WA55 CRPC 72 NA H, C, X ERG+
WA35 CRPC 71 NA R, H, C, X Negative
WA42 CRPC 61 NA H, C Negative
WA43-27 (celiac LN) CRPC 52 NA P, R, H, C Negative
WA43-44 (bladder) CRPC
WA43-71 (right lung) CRPC
WA46 CRPC 71 NA P, R, H, C, X Negative
WA49 CRPC 68 NA P, R, H, C ERG+
WA50 CRPC 78 NA P, R, H, C ERG+
WA51 CRPC 65 NA P, H, C, X Negative
WA52 CRPC 80 NA P, H, C ERG+
WA56 CRPC 79 NA P, R, H, C, X ERG+
WA57 CRPC 73 NA (NE diff) R, H, C, ERG+
WA59 CRPC 59 NA H, C, X Negative
WA60 CRPC 62 NA H, C ERG+
*Localized prostate cancer (PC) or castrate-resistant metastatic PC (CRPC).
†Age at diagnosis (PC) or death (CRPC).
‡Gleason score of profiled prostatectomy specimen for PC. CRPCs with neuroendocrine (NE) differ-
entiation are noted.
§C indicates chemotherapy; H, hormone therapy; P, prostatectomy; R, radiation; X, palliative radiation.
¶Rearrangements in ETS or RAF family genes.
Table W3. Prostate Cancer Exome Sequencing Statistics.
Sample Status Agilent SureSelect Human
All Exon Kit (Mb)










WA35 Tumor 50 51,712,500 170,916,320 13,331,472,960 10,558,678,026 5,238,994,222 101.31
Normal 50 51,712,500 157,827,174 12,310,519,572 9,722,413,350 4,443,761,328 85.93
WA42 Tumor 50 51,712,500 169,227,800 13,199,768,400 11,152,269,258 5,328,029,502 103.03
Normal 50 51,712,500 160,543,858 12,522,420,924 10,584,966,288 5,238,213,050 101.29
WA43 Tumor 43-27 50 51,712,500 106,207,750 8,284,204,500 7,078,252,896 3,474,444,817 67.19
Tumor 43-44 50 51,712,500 119,846,711 9,348,043,458 8,062,722,408 4,302,838,713 83.21
Tumor 43-71 50 51,712,500 115,921,897 9,041,907,966 7,819,368,804 3,702,454,417 71.60
Normal 50 51,712,500 109,694,911 8,556,203,058 7,301,239,530 3,538,639,763 68.43
WA46 Tumor 50 51,712,500 174,132,908 13,582,366,824 11,159,069,376 5,653,532,988 109.33
Normal 50 51,712,500 174,753,667 13,630,786,026 11,418,269,070 5,428,312,362 104.97
WA49 Tumor 50 51,712,500 155,083,960 12,096,548,880 10,251,439,692 5,091,480,149 98.46
Normal 50 51,712,500 150,941,382 11,773,427,796 9,990,123,234 5,142,727,707 199.45
WA50 Tumor 50 51,712,500 151,428,570 11,811,428,460 10,163,517,936 4,825,565,562 93.32
Normal 50 51,712,500 146,431,894 11,421,687,732 9,712,458,132 4,918,010,589 95.10
WA51 Tumor 50 51,712,500 165,709,454 12,925,337,412 10,739,425,398 4,824,644,281 93.30
Normal 50 51,712,500 170,866,524 13,327,588,872 11,006,378,916 5,103,100,934 98.68
WA52 Tumor 50 51,712,500 196,334,388 15,314,082,264 12,710,410,284 6,105,297,939 118.06
Normal 50 51,712,500 182,664,677 14,247,844,806 11,851,474,518 5,394,831,142 104.32
WA53 Tumor 38 37,806,033 170,043,479 13,263,391,362 11,275,509,726 6,813,696,982 180.23
Normal 38 37,806,033 160,836,761 12,545,267,358 10,592,709,894 6,593,161,035 174.39
WA54 Tumor 38 37,806,033 109,465,569 8,538,314,382 7,274,785,830 4,409,679,103 116.64
Normal 38 37,806,033 168,886,512 13,173,147,936 11,227,983,078 7,016,349,732 185.59
WA55 Tumor 38 37,806,033 169,683,500 13,235,313,000 11,190,529,662 6,730,794,029 178.03
Normal 38 37,806,033 168,001,511 13,104,117,858 11,095,714,656 6,872,481,717 181.78
WA56 Tumor 50 51,712,500 171,138,470 13,348,800,660 10,979,986,056 5,177,318,788 100.12
Normal 50 51,712,500 173,359,773 13,522,062,294 11,245,543,686 5,497,614,730 106.31
WA57 Tumor 50 51,712,500 172,761,810 13,475,421,180 10,834,401,240 4,778,197,473 92.40
Normal 50 51,712,500 169,816,928 13,245,720,384 10,482,745,260 5,096,773,379 98.56
WA59 Tumor 50 51,712,500 159,528,926 12,443,256,228 10,058,917,362 4,475,487,277 86.55
Normal 50 51,712,500 167,669,729 13,078,238,862 10,418,808,036 4,900,312,121 94.76
WA60 Tumor 50 51,712,500 166,908,169 13,018,837,182 10,453,483,014 4,569,838,785 88.37
Normal 50 51,712,500 163,743,302 12,771,977,556 10,272,887,664 4,726,398,012 91.40
Mean across samples 49,105,037 158,449,321 12,359,047,067 10,271,452,571 5,169,155,707 105.27
Table W4. Summary of Aberrations across 17 Lethal Metastatic Prostate Samples.
Sample All Gains (Copy Number
Ratio ≥ 1.25)
All Losses (Copy Number
Ratio ≤ 0.75)
High-level Gains (Copy Number
Ratio ≥ 2.0)
Homozygous Losses (Copy Number
Ratio ≤ 0.50)
No. Aberrations* Length of Altered
Genome (Mb)†
No. Aberrations* Length of Altered
Genome (Mb)†
No. Aberrations* Length of Altered
Genome (Mb)†
No. Aberrations* Length of Altered
Genome (Mb)†
WA35 233 407.5 70 280.2 35 26.5 9 1.2
WA42 12 286.0 81 428.1 0 0.0 19 19.7
WA43-27 53 334.6 56 538.0 18 23.1 9 0.7
WA43-44 51 368.5 61 492.3 23 30.1 9 0.7
WA43-71 490 849.5 609 379.0 25 23.3 89 25.9
WA46 596 720.5 79 71.1 112 108.2 7 0.5
WA49 173 404.7 43 264.8 29 26.1 9 37.5
WA50 88 429.2 96 183.1 3 1.2 17 3.4
WA51 30 273.4 81 538.3 3 101.5 22 56.4
WA52 33 240.8 55 79.8 0 0.0 3 3.5
WA53 93 332.9 117 513.3 18 22.5 17 18.8
WA54 100 353.1 65 475.7 19 7.7 9 30.7
WA55 104 506.3 83 282.6 29 58.7 18 75.5
WA56 51 421.9 71 406.2 2 3.5 18 70.2
WA57 57 421.3 78 639.6 11 26.2 34 144.6
WA59 306 562.5 282 277.2 37 31.7 28 28.0
WA60 743 433.6 746 912.0 19 21.4 59 67.9
Median 93 407.5 79 406.2 19 23.3 17 25.9
*Number of aberrations refers to the number of segments identified from segmentation analysis exceeding the given threshold.
†Length of altered genome refers to the combined length of these aberrant segments per sample, expressed in megabases.
